dropcys
lucane pharma - mercaptamine - corneal diseases; cystinosis - it-trattament tal-kornea ta ' cystine depożiti,.
heparesc
cytonet gmbh kg - - bniedem eteroloġiċi-ċelluli tal-fwied - disturbi taċ-Ċiklu ta 'l-urea, inborn - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - it-trattament ta ' l-urea disturbi fiċ-ċiklu (ucd).
istodax
celgene europe ltd. - romidepsin - limfoma, mhux hodgkin - aġenti antineoplastiċi - it-trattament ta ' t-cell lymphoma (ptcl),.
folotyn
allos therapeutics ltd - pralatrexate - limfoma, Ċellula-t - aġenti antineoplastiċi - it-trattament ta ' t-cell lymphoma,.
sumatriptan galpharm
galpharm healthcare ltd. - sumatriptan succinate - disturbi fl-emigranja
impulsor
pierre fabre medicament - milnacipran - fibromyalgia
milnacipran pierre fabre medicament
pierre fabre medicament - milnacipran - fibromyalgia
sovrima
centocor b.v. - idebenone - friedreich ataxia - psychoanaleptics, - it-trattament tal-friedreichâatassja.
natalizumab elan pharma
elan pharma international ltd. - natalizumab - marda ta 'crohn - immunostimulanti, - it-trattament ta attiva minn moderata sa gravi marda ta 'crohn għat-tnaqqis ta' sinjali u sintomi, u l-induzzjoni u l-manteniment ta ' rispons u remissjoni, fl-pazjenti li ma kellhomx rispons minkejja sħiħ u adegwat matul it-terapija b'kortikosterojde u l-immunosuppressant; jew li huma intolleranti għal, jew li jkollhom kontra-indikazzjonijiet mediċi għal terapiji bħal dawn.
hopveus
d&a pharma - sodium oxybate - substance withdrawal syndrome; alcohol abstinence - drogi oħra tas-sistema nervuża - substitution treatment for alcohol dependence within a framework of careful medical supervision along with continuous psychosocial support and social rehabilitation. treatment should be initiated only in patients resistant to existing interventions or in patients for whom existing therapies are contra-indicated or not recommended.